For Research Purposes Only. This page summarizes published preclinical and clinical research. It does not constitute medical advice and is not a recommendation for human use. Always consult a qualified healthcare professional.
Tirzepatide
Dual GIP/GLP-1 receptor agonist. FDA-approved as Mounjaro and Zepbound. Phase III trials demonstrated greater mean weight loss than GLP-1-only agents.
Overview
Tirzepatide is a 39-amino-acid synthetic peptide that functions as a dual agonist at both the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP is the other major incretin hormone, co-secreted with GLP-1 from the gut following nutrient intake. Its receptor activation contributes to insulin secretion, modulation of adipose tissue metabolism, and potentially direct effects on hypothalamic energy homeostasis pathways. Tirzepatide's dual-receptor engagement is hypothesized to produce synergistic effects beyond what GLP-1 agonism alone achieves, though the precise mechanistic contribution of GIP agonism to its weight loss efficacy remains an active area of research.
The SURMOUNT program — a series of Phase III trials evaluating tirzepatide specifically for obesity — represents some of the most significant pharmacological weight loss data published. SURMOUNT-1 (NEJM, 2022) enrolled 2,539 adults with obesity and demonstrated mean weight reductions of 16.0%, 21.4%, and 22.5% at 5mg, 10mg, and 15mg doses respectively over 72 weeks, compared to 2.4% for placebo. The highest-dose arm achieved 37.0% weight loss in a post-hoc analysis of completers. These figures substantially exceeded the weight loss benchmark established by semaglutide in STEP-1. The SURPASS program of trials, conducted in type 2 diabetes populations, demonstrated superiority of tirzepatide over semaglutide 1mg in head-to-head comparison (SURPASS-2, NEJM 2021) for both HbA1c reduction and weight loss.
Tirzepatide received FDA approval as Mounjaro (Eli Lilly) for type 2 diabetes in May 2022, and as Zepbound for chronic weight management in adults with obesity or overweight with at least one comorbidity in November 2023. Ongoing Phase IV investigation includes the SURMOUNT-MMO cardiovascular outcomes trial and studies in metabolic dysfunction-associated steatohepatitis (MASH), obstructive sleep apnea, and heart failure with preserved ejection fraction (HFpEF). Research-grade tirzepatide sold by peptide vendors is distinct from the pharmaceutical product and is intended for laboratory research purposes only.
Research Status
SURMOUNT-1 (Jastreboff et al., NEJM 2022): 20.9% mean weight loss at 72 weeks (15mg). SURPASS-2 (Frías et al., NEJM 2021): superior to semaglutide 1mg in T2D. SURMOUNT-4 (Aronne et al., JAMA 2024): weight loss maintained with continued treatment; withdrawal led to regain. SUMMIT trial: HFpEF outcomes data.
Common Research Protocols
Dosing above is from FDA-approved Mounjaro and Zepbound prescribing information. These protocols apply to the pharmaceutical product manufactured under GMP controls. Research-grade vials are not equivalent. This information is for educational reference only.
Storage & Handling
Lyophilized research tirzepatide should be stored at −20°C. Once reconstituted, store at 4°C and use within 28 days. Do not freeze reconstituted peptide. Pharmaceutical Mounjaro/Zepbound pens have separate storage requirements and should not be confused with research-grade vials.
What to Look for When Buying
Tirzepatide is a structurally complex 39-amino-acid peptide. Synthesis quality varies significantly between vendors, making independent third-party HPLC testing non-negotiable. Finnrick Analytics has tested tirzepatide from multiple vendors with notable variation in results.
Check Finnrick data carefully for this compound specifically: several vendors have passed purity thresholds but failed on quantity accuracy (significant underfill). A 10mg vial with only 7mg of active compound delivers meaningfully less than labeled.
The pharmaceutical Mounjaro/Zepbound pens use a specific proprietary formulation. Research-grade vials are lyophilized and require reconstitution — the dosing, handling, and administration differ entirely from the pharmaceutical product.
Given tirzepatide's high retail demand, it has attracted fraudulent and substandard vendors. Prioritize vendors with Finnrick test history spanning multiple batches, not just a single early test result.
If comparing tirzepatide across vendors on PepVendors, sort by purity grade first, then by price per mg — the purity differential between vendors is larger here than with simpler peptides like BPC-157.
Compare Vendor Pricing
PepVendors tracks live pricing for Tirzepatide across multiple vendors, updated weekly. Compare price per mg, available sizes, and purity data side by side.
Compare Tirzepatide prices →Third-Party Purity Data
Full data at finnrick.com →Independent HPLC test results from Finnrick Analytics. Purity values are averages across multiple samples. Check the Finnrick vendor page for batch-level detail.
For Research Purposes Only — Not Medical Advice. The information on this page is compiled from published peer-reviewed research, publicly available clinical trial data, and independent third-party testing results. It is intended solely as an educational reference for researchers.
Nothing on this page constitutes medical advice, a diagnosis, or a treatment recommendation. Peptides listed as research chemicals are not approved for human consumption unless explicitly noted as FDA-approved pharmaceuticals. PepVendors is a price comparison and information platform — we do not manufacture, sell, or distribute any compounds. Always consult a qualified and licensed healthcare professional before considering any compound for personal use.